Advanced Science (Aug 2024)
Mesenchymal Stem Cell Membrane‐Camouflaged Liposomes for Biomimetic Delivery of Cyclosporine A for Hepatic Ischemia‐Reperfusion Injury Prevention
- Haitian Chen,
- Wen Yin,
- Kang Yao,
- Jinliang Liang,
- Jianye Cai,
- Xin Sui,
- Xuegang Zhao,
- Jiebin Zhang,
- Jiaqi Xiao,
- Rong Li,
- Qiuli Liu,
- Jia Yao,
- Guohua You,
- Yasong Liu,
- Chenhao Jiang,
- Xiaotong Qiu,
- Tingting Wang,
- Qiang You,
- Yingcai Zhang,
- Mo Yang,
- Jun Zheng,
- Zong Dai,
- Yang Yang
Affiliations
- Haitian Chen
- Department of Hepatic Surgery and Liver Transplantation Center of The Third Affiliated Hospital Organ Transplantation Institute Sun Yat‐sen University Organ Transplantation Research Center of Guangdong Province Guangdong Province Engineering Laboratory for Transplantation Medicine Guangzhou 510630 China
- Wen Yin
- School of Biomedical Engineering Shenzhen Campus of Sun Yat‐sen University Shenzhen 518107 China
- Kang Yao
- Department of Hepatic Surgery and Liver Transplantation Center of The Third Affiliated Hospital Organ Transplantation Institute Sun Yat‐sen University Organ Transplantation Research Center of Guangdong Province Guangdong Province Engineering Laboratory for Transplantation Medicine Guangzhou 510630 China
- Jinliang Liang
- Guangdong Key Laboratory of Liver Disease Research The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou 510630 China
- Jianye Cai
- Department of Hepatic Surgery and Liver Transplantation Center of The Third Affiliated Hospital Organ Transplantation Institute Sun Yat‐sen University Organ Transplantation Research Center of Guangdong Province Guangdong Province Engineering Laboratory for Transplantation Medicine Guangzhou 510630 China
- Xin Sui
- Guangdong Key Laboratory of Liver Disease Research The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou 510630 China
- Xuegang Zhao
- Guangdong Key Laboratory of Liver Disease Research The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou 510630 China
- Jiebin Zhang
- Department of Hepatic Surgery and Liver Transplantation Center of The Third Affiliated Hospital Organ Transplantation Institute Sun Yat‐sen University Organ Transplantation Research Center of Guangdong Province Guangdong Province Engineering Laboratory for Transplantation Medicine Guangzhou 510630 China
- Jiaqi Xiao
- Department of Hepatic Surgery and Liver Transplantation Center of The Third Affiliated Hospital Organ Transplantation Institute Sun Yat‐sen University Organ Transplantation Research Center of Guangdong Province Guangdong Province Engineering Laboratory for Transplantation Medicine Guangzhou 510630 China
- Rong Li
- Guangdong Key Laboratory of Liver Disease Research The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou 510630 China
- Qiuli Liu
- The Biotherapy Center the Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou 510630 China
- Jia Yao
- Department of Hepatic Surgery and Liver Transplantation Center of The Third Affiliated Hospital Organ Transplantation Institute Sun Yat‐sen University Organ Transplantation Research Center of Guangdong Province Guangdong Province Engineering Laboratory for Transplantation Medicine Guangzhou 510630 China
- Guohua You
- Surgical ICU The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou 510630 China
- Yasong Liu
- Department of Hepatic Surgery and Liver Transplantation Center of The Third Affiliated Hospital Organ Transplantation Institute Sun Yat‐sen University Organ Transplantation Research Center of Guangdong Province Guangdong Province Engineering Laboratory for Transplantation Medicine Guangzhou 510630 China
- Chenhao Jiang
- Department of Hepatic Surgery and Liver Transplantation Center of The Third Affiliated Hospital Organ Transplantation Institute Sun Yat‐sen University Organ Transplantation Research Center of Guangdong Province Guangdong Province Engineering Laboratory for Transplantation Medicine Guangzhou 510630 China
- Xiaotong Qiu
- Guangdong Key Laboratory of Liver Disease Research The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou 510630 China
- Tingting Wang
- Guangdong Key Laboratory of Liver Disease Research The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou 510630 China
- Qiang You
- Guangdong Key Laboratory of Liver Disease Research The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou 510630 China
- Yingcai Zhang
- Department of Hepatobiliary Surgery People's Hospital of Xinjiang Uyghur Autonomous Region Urumqi 830001 China
- Mo Yang
- Department of Biomedical Engineering The Hong Kong Polytechnic University Hong Kong 999077 China
- Jun Zheng
- Department of Hepatic Surgery and Liver Transplantation Center of The Third Affiliated Hospital Organ Transplantation Institute Sun Yat‐sen University Organ Transplantation Research Center of Guangdong Province Guangdong Province Engineering Laboratory for Transplantation Medicine Guangzhou 510630 China
- Zong Dai
- School of Biomedical Engineering Shenzhen Campus of Sun Yat‐sen University Shenzhen 518107 China
- Yang Yang
- Department of Hepatic Surgery and Liver Transplantation Center of The Third Affiliated Hospital Organ Transplantation Institute Sun Yat‐sen University Organ Transplantation Research Center of Guangdong Province Guangdong Province Engineering Laboratory for Transplantation Medicine Guangzhou 510630 China
- DOI
- https://doi.org/10.1002/advs.202404171
- Journal volume & issue
-
Vol. 11,
no. 32
pp. n/a – n/a
Abstract
Abstract Hepatic ischemia‐reperfusion injury (HIRI) is a prevalent issue during liver resection and transplantation, with currently no cure or FDA‐approved therapy. A promising drug, Cyclosporin A (CsA), ameliorates HIRI by maintaining mitochondrial homeostasis but has systemic side effects due to its low bioavailability and high dosage requirements. This study introduces a biomimetic CsA delivery system that directly targets hepatic lesions using mesenchymal stem cell (MSC) membrane‐camouflaged liposomes. These hybrid nanovesicles (NVs), leveraging MSC‐derived proteins, demonstrate efficient inflammatory chemotaxis, transendothelial migration, and drug‐loading capacity. In a HIRI mouse model, the biomimetic NVs accumulated at liver injury sites entered hepatocytes, and significantly reduced liver damage and restore function using only one‐tenth of the CsA dose typically required. Proteomic analysis verifies the protection mechanism, which includes reactive oxygen species inhibition, preservation of mitochondrial integrity, and reduced cellular apoptosis, suggesting potential for this biomimetic strategy in HIRI intervention.
Keywords
